Abstract
Methods Gastric cancer between May 2002 and December 2020 and who had undergone resection of the primary cancer. We analyzed these patients to study the association between survival and tumor size by Cox proportional hazards model and restricted cubic splines.
Results A total of 1708 patients met the inclusion criteria, with a median age of 58 years. The distribution of tumor size was correlated with patients underwent different D2+ gastrectomy (P<0.001) and located different tumor site(P=0.002). The size of the patient’s tumor is closely related to the patient’s prognosis, as well as the overall survival of patients experienced proximal gastrectomy (P for trend= 0.002) and progression free survival of distal(P for trend= 0.03) and total gastrectomy (P for trend= 0.016) in fully adjusted model. Likewise, tumor size displayed its prognostic predictability in subgroup of upper 1/3, but only for overall survival in final model(P for trend= 0.045). Nonlinear relationship of different tumor size and D2+ gastrectomy or tumor site showed in restricted cubic splines, >5cm showed a significant impact in each group, but not for proximal gastrectomy (P for nonlinear=0.305). Overall survival and progression decreased progressively along with upgrading of tumor size accordingly.
Conclusions Tumor size>5cm can be seen as a line of demarcation of mortality and progression of gastric cancer after D2+gastrectomy, the hazard ratio began to rise when tumor size large than 5cm.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Shandong Provincial Natural Science Foundation(ZR2020MC073)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We consulted extensively with Ethics Committee of Shanxi Cancer Hospital and granted ethical approval from the ethics Committee of Shanxi Carcinoma Hospital(No:2022JC23)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The raw datasets generated during the current study are available from the corresponding author on reasonable request. All data analyzed during this study are included in this published article, Yifan Li is willing to share my data in this article.